Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2011

View Archived Issues

SK Biopharmaceuticals divulges preclinical data on SKL-A4R

Novartis discloses final results from EXIST-2 trial

Data presented from phase I trial of OPB-31121 in advanced solid malignancies

FDA accepts Amarin's NDA for AMR-101

Supernus commences U.S. phase IIb study of SPN-810

Multi-biomarker panel may monitor clinical disease activity in subjects with RA

Ongoing trial investigates effects of bevacizumab in neoplastic meningitis

Scientists at Karus Therapeutics prepare new PI3K inhibitors

French researchers patent novel kinase inhibitors

Astex Pharmaceuticals presents novel anticancer compounds

Phase IIb trial of RVX-208 in high-risk cardiovascular disease completes enrollment

Proximagen and Altacor enter agreement for serotonin 5-HT2C program

Cytokinetics begins third phase II trial of CK-2017357 in ALS

University of Edinburgh discloses new 11-beta-HSD1 inhibitors

FDA accepts Lodotra NDA for review

Compugen and DiscoveRx collaborate on novel peptide ligands

Omeros submits pediatric investigation plan to EMA for OMS-302

Japanese team synthesizes novel MMP-9 inhibitors

BMS obtains approval for additional indication for Paraplatin in Japan

Infinity and Mundipharma extend strategic alliance for PI3K inhibitors

FDA accepts Eliquis NDA for review

OncoVista secures CRO for phase Ib study of cordycepin

BioMarin begins study of GALNS in young patients with MPS IVA

Provectus gives update on program for PV-10 in metastatic melanoma

Soliris approved in Europe for treatment atypical hemolytic uremic syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...